pioglitazone has been researched along with MPTP Neurotoxicity Syndrome in 7 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of pioglitazone (10 and 30 mg/kg, p." | 1.35 | Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. ( Kaundal, RK; Kumar, P; More, S; Sharma, SS, 2009) |
| "Pretreatment with pioglitazone completely prevented these effects of MPTP." | 1.35 | The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. ( Chapman, H; Crook, B; Hows, ME; Medhurst, AD; Quinn, LP; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbiero, JK | 2 |
| Santiago, RM | 2 |
| Persike, DS | 1 |
| da Silva Fernandes, MJ | 1 |
| Tonin, FS | 1 |
| da Cunha, C | 1 |
| Lucio Boschen, S | 1 |
| Lima, MM | 2 |
| Vital, MA | 2 |
| Huot, P | 1 |
| Johnston, TH | 1 |
| Fox, SH | 1 |
| Brotchie, JM | 1 |
| Kumar, P | 1 |
| Kaundal, RK | 1 |
| More, S | 1 |
| Sharma, SS | 1 |
| Ariza, D | 1 |
| Morais, LH | 1 |
| Andreatini, R | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Lecointe, C | 1 |
| Devos, D | 1 |
| Bordet, R | 1 |
| Dehmer, T | 1 |
| Heneka, MT | 1 |
| Sastre, M | 1 |
| Dichgans, J | 1 |
| Schulz, JB | 1 |
| Quinn, LP | 1 |
| Crook, B | 1 |
| Hows, ME | 1 |
| Vidgeon-Hart, M | 1 |
| Chapman, H | 1 |
| Upton, N | 1 |
| Medhurst, AD | 1 |
| Virley, DJ | 1 |
7 other studies available for pioglitazone and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.
Topics: Animals; Avoidance Learning; Caspase 3; Disease Models, Animal; Dopamine; Drug Administration Schedu | 2014 |
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
Topics: Animals; Antiparkinson Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca | 2015 |
Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.
Topics: Administration, Oral; Animals; Avoidance Learning; Cognition; Discrimination Learning; Disease Model | 2009 |
Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Male; Mo | 2011 |
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activit | 2012 |
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.
Topics: Animals; Brain; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; I-kappa B Proteins; Ma | 2004 |
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Hypoglycemic | 2008 |